Pathophysiology and management of radiation-induced xerostomia

Journal of Supportive Oncology

Volumn 3, Issue 3, 2005, Pages 191-200

  Berk, Lawrence B ^a   Shivnani, Anand T ^b   Small Jr , William ^b  

^a Department of Radiation Oncology   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC AGENT; PILOCARPINE; PLACEBO;

ACUPUNCTURE; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSPHAGIA; HEAD AND NECK CANCER; HUMAN; HYPERHIDROSIS; NAUSEA AND VOMITING; NONHUMAN; PAROTID GLAND; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; RADIATION DOSE; RADIATION INJURY; REVIEW; SALIVARY GLAND DISEASE; SALIVARY GLAND FUNCTION; SALIVATION; TRANSPLANTATION; XEROSTOMIA;

ACUPUNCTURE THERAPY; AMIFOSTINE; CHOLINERGIC AGONISTS; HEAD AND NECK NEOPLASMS; HUMANS; PAROTID GLAND; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; SALIVARY GLANDS; SALIVATION; XEROSTOMIA;

EID: 20744432617     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Pedersen AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis 2002;8:117-129.
2. Carlson GW. The salivary glands: embryology, anatomy, and surgical applications. Surg Clin North Am 2000;80:261-273.
3. Flatau AT, Mills PR. Anatomy and physiology: regional anatomy. In: Norman JD, McGurk M, eds. Color Atlas and Text of the Salivary Glands: Diseases, Disorders and Surgery. London: Mosby-Wolfe; 1995:13-39.
4. Cawson RA, Gleeson MJ, Eveson JW. The Pathology and Surgery of the Salivary Glands. Oxford, England: Isis Medical Media; 1997.
5. Dawes C. Factors influencing salivary flow rate and composition. In: Edgar M, Dawes C, O'Mullane DM, eds. Saliva and Oral Health. 3rd ed. London: British Dental Association; 2004:32-49.
6. Dawes C. Circadian rhythms in human salivary flow rate and composition. J Physiol 1972;220:529-545.
7. Walsh NP, Montague JC, Callow N, Rowlands AV. Saliva flow rate, total protein concentration and osmolality as potential markers of whole body hydration status during progressive acute dehydration in humans. Arch Oral Biol 2004;49:149-154.
8. Ship JA, Fischer DJ. Metabolic indicators of hydration status in the prediction of parotid salivary-gland function. Arch Oral Biol 1999;44:343-350.
9. Dawes C. Circadian rhythms in the flow rate and composition of unstimulated and stimulated human submandibular saliva. J Physiol 1975;244:535-548.
10. Dawes C. Rhythms in salivary flow rate and composition. Int J Chronobiol 1974;2:253-279.
11. Macgregor ID. Effects of smoking on oral ecology: a review of the literature. Clin Prev Dent 1989;11:3-7.
12. Maier H, Born IA, Mail G. Effect of chronic ethanol and nicotine consumption on the function and morphology of the salivary glands. Klin Wochenschr 1988;66(suppl 11):140-150.
13. Roesink JM, Terhaard CH. The influence of clinical factors on human stimulated parotid flow rate in cancer and other patients. Oral Oncol 2002;38:291-295.
14. Parvinen T. Stimulated salivary flow rate, pH and lactobacillus and yeast concentrations in non-smokers and smokers. Scand J Dent Res 1984;92:315-318.
15. Conduit R, Coleman G. Conditioned salivation and associated dreams from REM sleep. Dreaming 1998;8:243-262.
16. Fischer D, Ship JA. Effect of age on variability of parotid salivary gland flow rates over time. Age Ageing 1999;28:557-561.
17. Bradley RM. Essentials of Oral Physiology. St. Louis, Mo: Mosby-Year Book, Inc.; 1995.
18. Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:28-46.
19. Bardow A, Nyvad B, Nauntofte B. Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ. Arch Oral Biol 2001;46:413-423.
20. Logemann JA, Smith CH, Pauloski BR, et al. Effects of xerostomia on perception and performance of swallow function. Head Neck 2001;23:317-321.
21. Hamlet S, Faull J, Klein B, et al. Mastication and swallowing in patients with postirradiation xerostomia. Int J Radiat Oncol Biol Phys 1997;37:789-796.
22. Wang SL, Zhao ZT, Li J, et al. Investigation of the clinical value of total saliva flow rates. Arch Oral Biol 1998;43:39-43.
23. Dawes C. How much saliva is enough for avoidance of xerostomia? Caries Res 2004;38:236-240.
24. Grotz KA, Genitsariotis S, Vehling D, Al-Nawas B. Long-term oral Candida colonization, mucositis and salivary function after head and neck radiotherapy. Support Care Cancer 2003;11:717-721.
25. Nicolatou-Galitis O, Sotiropoulou-Lontou A, Velegraki A, et al. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. Oral Oncol 2003;39:397-401.
26. Johansson G, Andersson G, Attstrom R, Glantz PO, Larsson K. The effect of salinum on the symptoms of dry mouth: a pilot study. Gerodontology 1994;11.46-49.
27. Hershkovich O, Nagler RM. Biochemical analysis of saliva and taste acuity evaluation in patients with burning mouth syndrome, xerostomia and/or gustatory disturbances. Arch Oral Biol 2004;49:515-522.
28. Mason DK, Harden RM, Rowan D, Alexander WD. Recording the pattern of salivary flow.J Dent Res 1966;45:1458-1463.
29. Adams BK, Al Attia HM, Parkar S. Salivary gland scintigraphy in Sjögren's syndrome: are quantitative indices the answer? Nucl Med Commun 2003;24:1011-1016.
30. Aung W, Murata Y, Ishida R, et al. Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren's syndrome. J Nucl Med 2001;42:38-43.
31. Wolff A, Herscovici D, Rosenberg M. A simple technique for the determination of salivary gland hypofunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:175-178.
32. Pai S, Ghezzi EM, Ship JA. Development of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:311-316.
33. University of Washington Surgical Outcomes and Research. Copies of the UW-QOL Scale. Available at http://depts.washington.edu/soar/projects/dxcat/hnca/qol_uw.htm. Accessed March 1, 2005.
34. Nagler RM.The enigmatic mechanism of irradiation-induced damage to the major salivary glands. Oral Dis 2002;8:141-146.
35. Fox PC. Acquired salivary dysfunction: drugs and radiation. Ann N Y Acad Sci 1998;842:132-137.
36. Ang KK, Stephens LC, Schultheis TE. Oral cavity and salivary glands. In: Scherer E, Streffer C, Trott K-R, eds. Radiopathology of Organs and Tissues. New York, NY: Springer-Verlag; 1991:283-311.
37. Burlage FR, Coppes RP, Meertens H, Stokman MA, Vissink A. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiother Oncol 2001;61:271-274.
38. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18:2226-2233.
39. Valdez IH, Atkinson JC, Ship JA, Fox PC. Major salivary gland function in patients with radiation-induced xerostomia: flow rates and sialochemistry. Int J Radiat Oncol Biol Phys 1993;25:41-47.
40. Price RE, Ang KK, Stephens LC, Peters LJ. Effects of continuous hyperfractionated accelerated and conventionally fractionated radiotherapy on the parotid and submandibular salivary glands of rhesus monkeys. Radiother Oncol 1995;34:39-46.
41. Nagler RM. Effects of head and neck radiotherapy on major salivary glands - animal studies and human implications. In Vivo 2003;17:369-375.
42. Jha N, Seikaly H, Harris J, et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiother Oncol 2003;66:283-289.
43. Eisbruch A, Ship JA, Martel MK, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation:techniques and early results. Int J Radiat Oncol Biol Phys 1996;36:469-480.
44. Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 2002;63:203-211.
45. Malouf JG, Aragon C, Henson BS, Eisbruch A, Ship JA. Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. Cancer Detect Prev 2003;27:305-310.
46. Munter MW, Karger CF, Hoffner SG, et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 2004;58:175-184.
47. Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;58:663-673.
48. Grdina DJ, Kataoka Y, Murley JS. Amifostine: mechanisms of action underlying cytoprotection and chemoprevention. Drug Metabol Drug Interact 2000;16:237-279.
49. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol 2000;72:425-435.
50. Dorr RT. Radioprotectants: pharmacology and clinical applications of amifostine. Semin Radiat Oncol 1998;8(4 suppl 1):10-13.
51. Brizel DM, Wasserman T. The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow-up of a prospective randomized trial. In: Program/Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 5536.
52. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-3345.
53. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:739-747.
54. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Subcutaneous administration of amifostine (Ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 2003;57:794-802.
55. Anne PR, Curran WJ Jr. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002;12(1 suppl 1):18-19.
56. Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 2002;29(6 suppl 19):57-60.
57. Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987;59:1123-1125.
58. Nagler RM, Laufer D. Protection against irradiation-induced damage to salivary glands by adrenergic agonist administration. Int J Radiat Oncol Biol Phys 1998;40:477-481.
59. Weaver ML, Tanzer JM, Kramer PA. Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. Pharm Res 1992;9:1064-1069.
60. Aromdee C, Ferguson MM, Ledger R, Wall J. A pilot study of the disposition of pilocarpine in plasma, saliva and urine after a single oral dose. Eur J Pharm Sci 1999;8:81-83.
61. Aromdee C, Fawcett JP, Ferguson MM, Ledger R. Serum pilocarpine esterase activity and response to oral pilocarpine. Biochem Mol Med 1996;59:57-61.
62. Aromdee C, Fawcett JP, Ledger R. Sensitive high-performance liquid chromatographic assay for pilocarpine in biological fluids using fluorescence derivatisation. J Chromatogr B Biomed Appl 1996;677:313-318.
63. Horiot JC, Lipinski F, Schraub S, et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 2000;55:233-239.
64. LeVeque FG, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-1131.
65. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for postirradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-395.
66. Zimmerman RP, Mark RJ, Tran LM, Juillard CF. Concomitant pilocarpine during head and neck irradiation is associated with decreased post-treatment xerostomia. Int J Radiat Oncol Biol Phys 1997;37:571-575.
67. Zimmerman RP, Mark RJ, Juilliard JF. Timing of pilocarpine treatment during head and neck radiotherapy: concomitant administration reduces xerostomia better than post-radiation pilocarpine. Int J Radiat Oncol Biol Phys 1996;36(suppl 1):236.
68. Warde P, O'Sullivan B, Aslanidis J, et al. A phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;54:9-13.
69. Scarantino CW, Le Veque F, Scott C, et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients: final results of RTOG 97-09. Int J Radiat Oncol Biol Phys 2001;51:85-86.
70. Hamlar DD, Schuller DE, Gahbauer RA, et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996;106-972-976.
71. Frydrych AM, Davies GR, Slack-Smith LM, et al. An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia. Aust Dent J 2002;47:249-253.
72. Bernardi R, Perin C, Becker FL, et al. Effect of pilocarpine mouthwash on salivary flow. Braz J Med Biol Res 2002;35:105-110.
73. Weber RS, Chambers MS, Posner M, et al. Phase III study of cevimeline for radiation-induced xerostomia. In: Program/Proceedings of the 108th Annual Meeting of the American Academy of Otolaryngology/Head and Neck Surgery; September 19-22, 2004; New York, NY. Abstract P116.
74. Blom M,Dawidson I,Fernberg JO,et al.Acupuncture treatment of patients with radiation-induced xerostomia. Eur J Cancer B Oral Oncol 1996;32B:182-190.
75. Blom M, Lundeberg T. Long-term follow-up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 2000;6:15-24.
76. Blom M, Kopp S, Lundeberg T. Prognostic value of the pilocarpine test to identify patients who may obtain long-term relief from xerostomia by acupuncture treatment. Arch Otolaryngol Head Neck Surg 1999;125:561-566.
77. Blom M, Dawidson I, Angmar-Mansson B. The effect of acupuncture on salivary flow rates in patients with xerostomia. Oral Surg Oral Med Oral Pathol 1992;73:293-298.
78. Johnstone PA, Peng YP, May BC, Inouye WS, Niemtzow RC. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001;50:353-357.
79. Wong RK, Jones GW, Sagar SM, Babjak AF, Whelan T. A phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:472-480.